All Releases
 |
Myrexis to Present at Rodman & Renshaw and UBS Conferences
Sep 2, 2010
|
10.5 KB |
|
| |
SALT LAKE CITY, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, is scheduled to present an overview of the Company at two upcoming conferences ...
|
|
Myrexis to Hold Conference Call to Discuss Fiscal Year 2010 Results
Aug 31, 2010
|
10.4 KB |
|
| |
SALT LAKE CITY, Aug. 31, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will hold a conference call on Thursday, September 9, 2010 at 4:30 p.m. ET (1:30 p.m. PT) to report financial results for its fourth quarter a...
|
|
Myriad Pharmaceuticals Formally Adopts Its Name Change to Myrexis, Inc. Effective July 1, 2010
Jun 30, 2010
|
14.8 KB |
|
| |
SALT LAKE CITY, June 30, 2010 (GLOBE NEWSWIRE) -- Effective July 1, Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) will change its name to Myrexis, Inc. The name change was previously approved by the Company's shareholders at a special meeting held on April 22, 2010. The Company's Common Stock will continue to trade on the Nasdaq Global Market stock...
|
|
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Jun 8, 2010
|
28.7 KB |
|
| |
SALT LAKE CITY, June 8, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
The Company's initiatives include: the expansion of th...
|
|
Myriad Pharmaceuticals Announces Presentations of Phase 2 Data of Azixa(TM) Demonstrating Durable Responses in Patients With Glioblastoma Multiforme and Metastatic Melanoma at ASCO 2010
Jun 7, 2010
|
11.5 KB |
|
| |
SALT LAKE CITY, June 7, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent gl...
|
|
Myriad Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
May 26, 2010
|
9.5 KB |
|
| |
SALT LAKE CITY, May 26, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the treatment of cancer and HIV infection, today announced that Adrian N. Hobden, President and CEO of Myriad Pharmaceuticals, will provide an overview of the ...
|
|
Myriad Pharmaceuticals Announces Presentations at 2010 ASCO Annual Meeting
May 20, 2010
|
15.2 KB |
|
| |
SALT LAKE CITY, May 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that it will be reporting data on its lead oncology candidate, Azixa™ (MPC-6827), currently in three Phase 2 studies for the treatment of glioblastoma multiforme and metastatic melanoma, during poster presentations at the 2010 Annual American...
|
|
Myriad Pharmaceuticals Reports Third Quarter FY' 2010 Financial Results
May 17, 2010
|
20.1 KB |
|
| |
SALT LAKE CITY, May 17, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its third fiscal quarter ended March 31, 2010. The Company ended the quarter with $148.4 million in cash, cash equivalents and marketable securities and subsequently received a payment of $12.7 million from Javelin Pharm...
|
|
Myriad Pharmaceuticals Presents Data From Nampt Inhibitor Program at AACR 101st Annual Meeting
Apr 20, 2010
|
10.4 KB |
|
| |
SALT LAKE CITY, April 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preclinical data characterizing MPI-0486348, the lead compound in the company's Nicotinamide phosphoribosyltransferase (Nampt) inhibitor pre-clinical program at the American Association for Cancer Research (AACR) 101st ...
|
|
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Apr 19, 2010
|
13.6 KB |
|
| |
SALT LAKE CITY, April 19, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals (NYSE Amex:JAV).
In accordance with the terms of the merger agreement, Myriad Pharmaceuticals is entitled to the payment from J...
|
|
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Apr 12, 2010
|
16.6 KB |
|
| |
SALT LAKE CITY, April 12, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc (Nasdaq:MYRX) today announced that it has received a notice from Javelin Pharmaceuticals, Inc. (NYSE Amex:JAV) of its intent to terminate the merger agreement between the two companies (the "Merger Agreement"). The notice stated that Javelin has received a competing acq...
|
|
Myriad Pharmaceuticals, Inc. Sets Date for Special Stockholder Meeting to Approve Merger with Javelin Pharmaceuticals, Inc.
Mar 15, 2010
|
12.2 KB |
|
| |
SALT LAKE CITY, March 15, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX), announced today that a registration statement on Form S-4 relating to the proposed merger with Javelin Pharmaceuticals, Inc. has been declared effective by the Securities and Exchange Commission and mailing of the joint proxy statement/prospectus containe...
|
|
Myriad Pharmaceuticals Reports Second Quarter FY' 2010 Financial Results
Feb 16, 2010
|
22.8 KB |
|
| |
SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its second fiscal quarter ended December 31, 2009.
"We are pleased with the progress we have made over the past seven months," said Adrian N. Hobden Ph.D., President and CEO of Myriad Pharmaceuticals, Inc. "We continu...
|
|
Myriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8th
Feb 3, 2010
|
11.6 KB |
|
| |
SALT LAKE CITY, Feb. 3, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Adrian N. Hobden, Ph.D., President and Chief Executive Officer, will present at Biotechnology Industry Organization’s CEO & Investor Confere...
|
|
FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)
Feb 2, 2010
|
12.6 KB |
|
| |
SALT LAKE CITY, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’ submission and filed a New Drug Application (NDA) for Dyloject™, an investigational, injectable NSAID for the management of acute moderate-to-severe postop...
|
|
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Dec 18, 2009
|
23.8 KB |
|
| |
Creates Pipeline With Potential Near-Term Product Launch of
Dyloject(TM) and Portfolio of Early-, Mid- and Late-Stage
Drug Candidates in Cancer, HIV and Pain
Joint Conference Call Scheduled for 9:00 AM ET
Friday, December 18, 2009
SALT LAKE CITY and CAMBRIDGE, Mass., Dec. 18, ...
|
|
Myriad Pharmaceuticals Initiates Phase 2b Study of MPC-4326 in a Genetically-Identified Responder Population
Dec 1, 2009
|
12.1 KB |
|
| |
SALT LAKE CITY, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the initiation of a Phase 2b study of MPC-4326, a first-in-class, small molecule inhibitor of HIV-1 maturation.
This multicenter, randomized, open-label study is designed to determine MPC-4326 efficacy in an optimized background regime. The...
|
|
Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
Nov 23, 2009
|
9.3 KB |
|
| |
SALT LAKE CITY, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) announced today that Adrian Hobden, President and CEO, is scheduled to present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference, at 10:00 a.m. Eastern on December 1, 2009, at the New York Palace Hotel in New York City.
Th...
|
|
Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma
Nov 18, 2009
|
12.8 KB |
|
| |
SALT LAKE CITY, Nov. 18, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa(TM) (MPC-6827), a microtubule destabilizing agent in stage 4 melanoma patients. Azixa is in two additional phase 2 studies in recurrent glioblastoma multiforme...
|
|
Myriad Pharmaceuticals Confirms That MPC-3100, a Fully-Synthetic Hsp90 Inhibitor, is Orally-Bioavailable in Patients in Phase 1 Studies
Nov 16, 2009
|
12.5 KB |
|
| |
SALT LAKE CITY, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preliminary phase 1 data for MPC-3100, its fully-synthetic small molecule Hsp90 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.
In vivo studies with MPC-3100 induced tumor regress...
|
|
|
